SCHEMBL5285855

SCHEMBL5285855

COc1ccccc1Nc1ccc(S(=O)(=O)Nc2ccccc2F)c2nonc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 4/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
GAA P10253 1/20 0.54
ALDH1A1 P00352 5/20 0.51
MAPT P10636 2/20 0.51
KMT2A Q03164 5/20 0.47
MEN1 O00255 3/20 0.47
MAPK1 P28482 1/20 0.47
ACLY P53396 1/20 0.44
GFER P55789 1/20 0.43
NPC1 O15118 1/20 0.42
TSHR P16473 1/20 0.42
SLC40A1 Q9NP59 1/20 0.42
BRD4 O60885 2/20 0.41
BRD2 P25440 2/20 0.41
BRD3 Q15059 2/20 0.41
KDM4E B2RXH2 1/20 0.41
HTT P42858 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
PTGS1 P23219 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5295964 0.89 POLB (0.50) POLBSMN1; SMN2GAAALDH1A1MAPT
SCHEMBL5281134 0.85 ALDH1A1 (0.59) POLBSMN1; SMN2GAAALDH1A1MAPT
SCHEMBL5244715 0.78 NPC1 (0.55) POLBSMN1; SMN2ALDH1A1MAPTKMT2A
SCHEMBL5280376 0.78 POLB (0.55) POLBSMN1; SMN2ALDH1A1MAPTKMT2A
SCHEMBL5244817 0.77 RORA (0.53) POLBSMN1; SMN2GAAALDH1A1MAPT
SCHEMBL6392197 0.76 KMT2A (0.47) POLBSMN1; SMN2GAAALDH1A1MAPT
SCHEMBL5243631 0.75 ALDH1A1 (0.58) POLBSMN1; SMN2ALDH1A1MAPTKMT2A
SCHEMBL6396298 0.75 ALDH1A1 (0.75) POLBSMN1; SMN2GAAALDH1A1MAPT
SCHEMBL5282149 0.75 BRD4 (0.52) POLBSMN1; SMN2ALDH1A1MAPTKMT2A
SCHEMBL5296878 0.71 ALDH1A1 (0.49) POLBSMN1; SMN2GAAALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758873-A1 UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2007-03-07 EP claimed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO claimed
WO-2008115259-A2 DERIVATIVES OF BENZOXADIAZOLE SUITABLE FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES RIGEL PHARMACEUTICALS, INC. (US) 2008-09-25 WO disclosed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO disclosed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282818-A1 Ubiquitin ligase inhibitors NEDD4, TRAF6, XIAP POLB 2997/4885SMN1; SMN2 3058/4885GAA 488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.